1. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue

   • Ian Joseph Cohen

   Review Article 28 April 2017 Pages: 1057 - 1065

2. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

   • Hang Quach
   • Darrell White
   • Martin Gyger

   Original Article Open access 19 April 2017 Pages: 1067 - 1076

   

3. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer

   • Sotaro Sadahiro
   • T. Suzuki
   • H. Nagase

   Original Article Open access 17 April 2017 Pages: 1077 - 1085

   

4. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study

   • Jianyuan Zhang
   • Shaojun Chen
   • Hongwei Jiang

   Original Article 20 April 2017 Pages: 1087 - 1097

   

5. A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer

   • Feng Sun
   • Ruizhe Zhao
   • Shujie Xia

   Original Article 18 April 2017 Pages: 1099 - 1107

   

6. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis

   • Xuewei Chen
   • Liping Liu
   • Jianxing He

   Original Article 13 May 2017 Pages: 1109 - 1117

   

7. Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

   • Yvonne Y. Lau
   • Wen Gu
   • Michael Shi

   Original Article 19 April 2017 Pages: 1119 - 1128

   

8. CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis

   • Yen-Yun Wang
   • Yuk-Kwan Chen
   • Shyng-Shiou F. Yuan

   Original Article 12 May 2017 Pages: 1129 - 1140

   

9. Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

   • Yun Leng
   • Jian Hou
   • Wenming Chen

   Original Article 12 May 2017 Pages: 1141 - 1149

   

10. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy

    • Christopher P. Leamon
    • Joseph A. Reddy
    • Yu Wang

    Original Article 27 April 2017 Pages: 1151 - 1160

    

11. Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer

    • Sang-Won Kim
    • O Kyu Noh
    • Dukyong Yoon

    Original Article 26 April 2017 Pages: 1161 - 1167

    

12. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

    • Masafumi Ikeda
    • Hideaki Takahashi
    • Hideki Ueno

    Original Article 27 April 2017 Pages: 1169 - 1177

    

13. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese

    • Yuko Tanabe
    • Chikako Shimizu
    • Yasuhiro Fujiwara

    Original Article 26 April 2017 Pages: 1179 - 1186

    

14. MITF suppression by CH5552074 inhibits cell growth in melanoma cells

    • Satoshi Aida
    • Yukiko Sonobe
    • Takakazu Mizuno

    Original Article 26 April 2017 Pages: 1187 - 1193

    

15. In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells

    • Elham Mousavi
    • Shahrzad Tavakolfar
    • Mona Salimi

    Original Article 27 April 2017 Pages: 1195 - 1203

    

16. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer

    • Y. L. Xu
    • R. Yao
    • Q. Sun

    Original Article Open access 10 May 2017 Pages: 1205 - 1213

    

17. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer

    • Yu Nishijima-Futami
    • Seigo Minami
    • Takashi Kijima

    Original Article 28 April 2017 Pages: 1215 - 1220

    

18. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors

    • Tufia Haddad
    • Rui Qin
    • Julian Molina

    Original Article 05 May 2017 Pages: 1221 - 1227

    

19. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum

    • Takumi Fujiwara
    • Hirotsugu Kenmotsu
    • Toshiaki Takahashi

    Original Article 28 April 2017 Pages: 1229 - 1237

    

20. Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab

    • Georgina Meneses-Lorente
    • Christine McIntyre
    • Martin Weisser

    Original Article 11 May 2017 Pages: 1239 - 1247

    

21. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme

    • Anna M. Bielecka-Wajdman
    • Marta Lesiak
    • Ewa Obuchowicz

    Original Article 12 May 2017 Pages: 1249 - 1256

    

22. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors

    • Sandrine Aspeslagh
    • Kunwar Shailubhai
    • Jean-Charles Soria

    Clinical Trial Report 19 April 2017 Pages: 1257 - 1265

    

23. Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations

    • Andrea Ballerini
    • Federico Moro
    • Massimo Zucchetti

    Short Communication 19 April 2017 Pages: 1267 - 1271

    

24. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma

    • Antoine Thiery-Vuillemin
    • Emeline Orillard
    • Bernard Royer

    Short Communication 27 April 2017 Pages: 1273 - 1276